Adagrasib, also known as AMG 510, is a targeted therapy drug used for the treatment of non-small cell lung cancer (NSCLC) with a specific KRAS mutation.
It is a small molecule inhibitor that blocks the activity of the KRAS protein,
which is a key driver of cancer growth in many cases of NSCLC.
Targeted therapy: Adagrasib is a targeted therapy,
meaning it specifically targets a particular molecule involved in the growth and survival of cancer cells.